Korro Bio, Inc. (KRRO)
- Previous Close
58.53 - Open
59.97 - Bid 61.08 x 100
- Ask 64.25 x 100
- Day's Range
58.22 - 63.30 - 52 Week Range
9.15 - 97.91 - Volume
28,091 - Avg. Volume
32,785 - Market Cap (intraday)
583.53M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
130.00
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
www.korrobio.comRecent News: KRRO
Performance Overview: KRRO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRRO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRRO
Valuation Measures
Market Cap
583.53M
Enterprise Value
450.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.43
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.77%
Return on Equity (ttm)
-69.16%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-81.17M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
166.15M
Total Debt/Equity (mrq)
19.54%
Levered Free Cash Flow (ttm)
-47.69M